

[Insulin \(human, intermediate-acting\)](#)

Essential medicine status

Section:

[18. Medicines for endocrine disorders 18.5. Medicines for diabetes 18.5.1. Insulins](#)

ATC codes: [A10AC01](#)

Indication

Type 2 diabetes mellitus ICD11 code: [5A11](#)

INN

Isophane insulin

Medicine type

Biological agent

List type

Core

Additional notes

including quality-assured biosimilars

Formulations

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin ; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin ; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin ; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1984 ([TRS 722](#))

Changed in 1987 ([TRS 770](#))

Changed in 1997 ([TRS 882](#))

Changed in 2023 ([TRS 1049](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Biological

Wikipedia

[Insulin \(human, intermediate-acting\)](#)

DrugBank

[Insulin \(Insulin Human\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the medicine description be updated to replace 'Intermediate-acting insulin' with 'Insulin (human, intermediate-acting)'.